Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115


Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis.

Lawn SD, Wood R.

J Infect Dis. 2011 Nov 15;204 Suppl 4:S1159-67. doi: 10.1093/infdis/jir411. Review.


Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration.

Achkar JM, Lawn SD, Moosa MY, Wright CA, Kasprowicz VO.

J Infect Dis. 2011 Nov 15;204 Suppl 4:S1130-41. doi: 10.1093/infdis/jir450. Review.


Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

Lancet Infect Dis. 2012 Mar;12(3):201-9. doi: 10.1016/S1473-3099(11)70251-1. Epub 2011 Oct 17.


Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices.

Ballif M, Renner L, Claude Dusingize J, Leroy V, Ayaya S, Wools-Kaloustian K, Cortes CP, McGowan CC, Graber C, Mandalakas AM, Mofenson LM, Egger M, Kumara Wati KD, Nallusamy R, Reubenson G, Davies MA, Fenner L; International Epidemiologic Databases to Evaluate AIDS (IeDEA); International Epidemiologic Databases to Evaluate AIDS IeDEA.

J Pediatric Infect Dis Soc. 2015 Mar;4(1):30-8. doi: 10.1093/jpids/piu020. Epub 2014 Mar 28.


Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?

Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W.

Expert Rev Mol Diagn. 2010 Oct;10(7):937-46. doi: 10.1586/erm.10.67. Review.


Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

AIDS. 2012 Aug 24;26(13):1635-43. doi: 10.1097/QAD.0b013e3283553685.


Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test.

Bodmer T, Ströhle A.

J Vis Exp. 2012 Apr 9;(62):e3547. doi: 10.3791/3547.


New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance.

Pai M, Kalantri S, Dheda K.

Expert Rev Mol Diagn. 2006 May;6(3):423-32. Review.


[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.


Performance evaluation of three commercial molecular assays for the detection of Mycobacterium tuberculosis from clinical specimens in a high TB-HIV-burden setting.

Matabane MM, Ismail F, Strydom KA, Onwuegbuna O, Omar SV, Ismail N.

BMC Infect Dis. 2015 Nov 9;15:508. doi: 10.1186/s12879-015-1229-9.


The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce.

Peter JG, Theron G, Muchinga TE, Govender U, Dheda K.

PLoS One. 2012;7(7):e39966. doi: 10.1371/journal.pone.0039966. Epub 2012 Jul 9.


The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.

Pimkina E, Zablockis R, Nikolayevskyy V, Danila E, Davidaviciene E.

Respir Med. 2015 Nov;109(11):1484-9. doi: 10.1016/j.rmed.2015.07.006. Epub 2015 Jul 11.


Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand.

Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, Varma JK.

BMC Infect Dis. 2010 May 20;10:123. doi: 10.1186/1471-2334-10-123.


Nucleic acid amplification tests for diagnosis of smear-negative TB in a high HIV-prevalence setting: a prospective cohort study.

Davis JL, Huang L, Worodria W, Masur H, Cattamanchi A, Huber C, Miller C, Conville PS, Murray P, Kovacs JA.

PLoS One. 2011 Jan 27;6(1):e16321. doi: 10.1371/journal.pone.0016321.


[New diagnostic tests for tuberculosis in southern countries: from theory to practice in southern countries].

Bonnet M.

Rev Mal Respir. 2011 Dec;28(10):1310-21. doi: 10.1016/j.rmr.2011.10.002. Epub 2011 Nov 8. French.


The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.

Dowdy DW, Chaisson RE, Moulton LH, Dorman SE.

AIDS. 2006 Mar 21;20(5):751-62.


Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic.

O'Grady J, Bates M, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Maeurer M, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A.

Clin Infect Dis. 2012 Nov;55(9):1171-8. doi: 10.1093/cid/cis631. Epub 2012 Jul 17. Erratum in: Clin Infect Dis. 2013 Jan;56(2):313.


Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?

Kirwan DE, Cárdenas MK, Gilman RH.

Am J Trop Med Hyg. 2012 Aug;87(2):197-201. doi: 10.4269/ajtmh.2012.12-0107.


Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis.

Kerkhoff AD, Wood R, Vogt M, Lawn SD.

PLoS One. 2014 Jul 30;9(7):e103285. doi: 10.1371/journal.pone.0103285. eCollection 2014.


Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria.

Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, Kreiswirth BN, Lawn SD.

BMC Infect Dis. 2012 Feb 27;12:47. doi: 10.1186/1471-2334-12-47.

Supplemental Content

Support Center